Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical experience with azlocillin.

W E Sanders

    The Journal of Antimicrobial Chemotherapy
    |May 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Mezlocillin and azlocillin are new ureidopenicillins with broad-spectrum activity. Mezlocillin is effective against Enterobacteriaceae, while azlocillin is preferred for Pseudomonas aeruginosa infections.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Potential impact of the VITEK 2 system and the Advanced Expert System on the clinical laboratory of a university-based hospital.

    Journal of clinical microbiology·2001
    Same author

    Radiofrequency catheter ablation of supraventricular tachycardia substrates after mustard and senning operations for d-transposition of the great arteries.

    Journal of the American College of Cardiology·2000
    Same author

    Ability of the VITEK 2 advanced expert system To identify beta-lactam phenotypes in isolates of Enterobacteriaceae and Pseudomonas aeruginosa.

    Journal of clinical microbiology·2000
    Same author

    A pilot study of antibiotic cycling in a hematology-oncology unit.

    Infection control and hospital epidemiology·2000
    Same author

    Cefepime-aztreonam: a unique double beta-lactam combination for Pseudomonas aeruginosa.

    Antimicrobial agents and chemotherapy·1998
    Same author

    Ischaemia of the index finger and thumb secondary to thrombosis of the radial artery in the anatomical snuffbox.

    Journal of hand surgery (Edinburgh, Scotland)·1998
    Same journal

    Emerging resistance in staphylococci following long-term dalbavancin treatment for prosthetic joint infections.

    The Journal of antimicrobial chemotherapy·2026
    Same journal

    Microbiology testing around the time of antibiotic initiation among residents of long-term care facilities.

    The Journal of antimicrobial chemotherapy·2026
    Same journal

    Insights into the mechanisms underlying cell wall-active agents and gentamicin bactericidal synergism against Enterococcus faecalis.

    The Journal of antimicrobial chemotherapy·2026
    Same journal

    Re-evaluating the 14-day rule: short-course antifungal therapy for uncomplicated candidaemia in a multicentre cohort study.

    The Journal of antimicrobial chemotherapy·2026
    Same journal

    Impact of selective digestive decontamination on the pangenome composition of ESBL-E. coli.

    The Journal of antimicrobial chemotherapy·2026
    Same journal

    Compounds of the γ-carboline family inhibit trans-translation.

    The Journal of antimicrobial chemotherapy·2026
    See all related articles

    Area of Science:

    • Pharmacology and Infectious Diseases

    Background:

    • Introduction of mezlocillin and azlocillin, novel semi-synthetic ureidopenicillins.
    • Assessment of their broad-spectrum antimicrobial activity against various bacterial pathogens.

    Observation:

    • Comparable potency against Gram-positive, fastidious Gram-negative organisms, and anaerobes.
    • Differential activity: mezlocillin against Enterobacteriaceae, azlocillin against Pseudomonas species.

    Findings:

    • Mezlocillin demonstrates superior activity against Enterobacteriaceae.
    • Azlocillin exhibits greater potency against Pseudomonas species.

    Implications:

    • Clinical guidance suggests mezlocillin for Enterobacteriaceae infections.
    • Azlocillin is recommended for infections caused by Pseudomonas, particularly Pseudomonas aeruginosa.

    Related Experiment Videos

  • Clinical and laboratory findings support the use of azlocillin in treating serious Pseudomonas infections.